Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990071/S067

SMARTABLATE System Interface Cable (D-1303-02-S)

Biosense Webster, Inc. · Decision date Sep 15, 2025

FDA DECISIONP990071/S067

What did the FDA decide?

FDA records P990071/S067 as a supplement to PMA P990071, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 15, 2025.

FDA approval order statement

an alternative subassembly manufacturer for the SMARTABALTE System Interface Cable (D-1303-02-S)
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 15, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P990071/S067
Regulatory pathway
PMA supplement
Product code
LPB
Decision code
OK30
Decision date
Sep 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P990071/S067 received

    Application receipt date recorded by FDA.

  2. P990071/S067 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P990071. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990071

Product / regulatory recordCompanyPathwayDecision dateSource
nGEN PumpP990071/S068
Biosense Webster, Inc.PMA supplementDec 23, 2025FDA

Explore the linked device profile

Other records with product code LPB

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Irvine Biomedical, Inc.PMA supplementSep 3, 2026FDA
Ampere GeneratorP040014/S051
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA
Ampere GeneratorP960016/S094
St Jude MedicalPMA supplementAug 7, 2026FDA
Stereotaxis, Inc.PMA supplementJul 31, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records